Introduction {#s1}
============

The mechanical environment is an important determinant of bone health, as emphasized by a consistent bone loss in astronauts exposed to microgravity or in paralyzed or bedridden patients ([@bib27]). Gravitational and muscle forces act on the skeleton during physical activity resulting in a complex combination of shear forces, strains and pressures. Bone-embedded osteocytes and bone-forming osteoblasts are widely regarded as the mechanosensitive cells in the skeletal system ([@bib42]).

Following mechanical stimulation of rodent and human osteoblasts, transient intracellular free calcium (\[Ca^2+^\]~i~) elevations and ATP release are among the earliest detectable events, which result in autocrine and paracrine purinergic (P2) receptor signaling ([@bib30]; [@bib31]; [@bib10]). Vesicular release of lysosomes or secretory vesicles, or conductive release via channels such as Maxi anion channels, Volume-regulated anion channels (VRAC), Connexins or Pannexins are the main mechanisms of regulated ATP release in mammalian cells ([@bib24]). Pathological ATP spillage also occurs from traumatically damaged cells ([@bib3]). Of interest, non-lethal membrane injury has been demonstrated *in vivo* in several tissues ([@bib23]), including bone ([@bib44]), under physiological conditions. The mechanism of facilitated cell membrane repair has been described and involves Ca^2+^/PKC-dependent vesicular exocytosis ([@bib40]). However, the contribution of non-lethal cell injury to ATP release and related mechanotransductive purinergic signaling remains unclear.

The goal of this study was to examine the mechanism of ATP release from mechanically stimulated cells of the osteoblastic lineage. Since we have previously demonstrated that transient membrane disruption is required to induce global \[Ca^2+^\]~i~ elevations in osteoblasts ([@bib20]), we were particularly interested in understanding the contribution of membrane injury to mechanically induced ATP release. Mechanical forces were applied by local membrane deformation or turbulent fluid shear stress *in vitro* to BMP-2 transfected C2C12 osteoblastic cells (C2-OB), primary bone marrow (BM-OB) and compact bone (CB-OB)-derived osteoblasts and changes in \[Ca^2+^\]~i~, vesicular exocytosis, membrane permeability and ATP release were assessed. The prevalence of membrane injury in osteocytes at physiological and supraphysiological mechanical strain levels was investigated following *in vivo* cyclic compressive tibial loading of 10-week-old female C57Bl/6J mice.

Results {#s2}
=======

Mechanically stimulated osteoblasts release ATP that induces calcium responses in non-stimulated neighboring cells {#s2-1}
------------------------------------------------------------------------------------------------------------------

Osteoblasts from three different sources, C2-OB, CB-OB, and BM-OB, were loaded with \[Ca^2+^\]~i~ dye Fura2 and mechanically stimulated with a glass micropipette, which induced qualitatively similar transient global \[Ca^2+^\]~i~ elevations, consistent with prior work ([@bib30]; [@bib31]; [@bib10]) ([Figure 1A--C](#fig1){ref-type="fig"}, [Figure 1---video 1](#fig1video1){ref-type="video"}). L-type voltage-sensitive calcium channel (VSCC) inhibitor Nifedipine and P2 antagonist PPADS significantly reduced the amplitude of mechanically-stimulated \[Ca^2+^\]~i~ transients ([Figure 1D](#fig1){ref-type="fig"}). L-type VSCC activation occurred gradually ([Figure 1E](#fig1){ref-type="fig"}) while the P2 receptor-driven component of the response peaked within seconds of stimulation ([Figure 1F](#fig1){ref-type="fig"}). Together, L-type VSCC and P2 receptor-driven component accounted for \~50% of the mechanical stimulated \[Ca^2+^\]~i~ transient. Consistent with previous reports ([@bib30]; [@bib31]; [@bib10]), shortly after a single osteoblast was mechanically stimulated, neighboring cells exhibited delayed secondary \[Ca^2+^\]~i~ responses ([Figure 1G](#fig1){ref-type="fig"}). Pharmacological interventions revealed that P2 receptors mediated the secondary response in all three osteoblast models, while a tendency for GAP junction involvement was observed in BM-OB responses ([Figure 1H](#fig1){ref-type="fig"}). Puff application of 10 µM ATP mimicked the appearance of secondary responders in C2-OB ([Figure 1I](#fig1){ref-type="fig"}).

![Osteoblasts are mechanosensitive\
(**A-C**) Single Fura2-loaded C2-OB (**A**), CB-OB (**B**) or BM-OB (**C**) (*Top*: ALP staining) were stimulated with micropipette and \[Ca^2+^\]~i~ was recorded ([Figure 1---video 1](#fig1video1){ref-type="video"}). *Bottom*: representative traces (*black*), means ± SEM (*red*) (**D**) Amplitudes of mechanically evoked \[Ca^2+^\]~i~ transients in osteoblasts pretreated with vehicle, Nif, Sur or PPADS (see Materials and methods for abbreviations, targets and doses). Means ± SEM, n = 6--15 stimulated cells, normalized to vehicle. (**E, F**) Contribution of L-type VSCC (**E**, n = 10) and P2 receptors (**F**, n = 12) to mechanically evoked \[Ca^2+^\]~i~ transients in C2-OB as comparison and difference (*insets*) of mean ±SEM of vehicle and treatment \[Ca^2+^\]~i~ transients. (**G**) \[Ca^2+^\]~i~ in the stimulated (primary) and neighboring (secondary) C2-OB. *Top*: pseudocolor of 340/380 ratio, *white arrows*: directions of signal propagation, *bottom*: \[Ca^2+^\]~i~ transients, *red arrows*: top panel time points. (**H**) Secondary responsiveness in cultures pretreated with vehicle, Sur, PPADS, Cbx, FFA or Oct. Means ± SEM, n = 7--21 stimulated primary responses, normalized to vehicle. (**H**) \[Ca^2+^\]~i~ transients induced by mechanical stimulation of single C2-OB (*left*, red curve) or puff application of 10 µM ATP (*right*). For [Figure 1](#fig1){ref-type="fig"}, \*significance between treatment and control by ANOVA. Source data for [Figure 1](#fig1){ref-type="fig"} is provided in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.37812.005Figure 1---source data 1.](elife-37812-fig1){#fig1}

We used a luciferin fluorescence-based imaging technique ([@bib36]) to directly measure ATP release (\[ATP\]~e~) ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Simultaneous recording of \[ATP\]~e~ and \[Ca^2+^\]~i~ demonstrated that ATP release occurred within seconds after mechanical stimulation (time to peak release: 1.64 ± 0.36 s) and preceded the onset of \[Ca^2+^\]~i~ responses in neighboring cells ([Figure 2](#fig2){ref-type="fig"}). We measured pericellular \[ATP\]~e~ concentrations in the range of 0.05--80.5 µM corresponding to a release of 70 ± 24 amole ATP from a single mechanically stimulated osteoblast ([Figure 2B](#fig2){ref-type="fig"}). Pericellular \[ATP\]~e~ significantly correlated with the percentage of secondary responders ([Figure 2C](#fig2){ref-type="fig"}).

![ATP release following mechanical stimulation of a single osteoblast.\
(**A**) Fura2-loaded C2-OB bathed in luciferin/luciferase containing PS was micropipette-stimulated. *Top*: 380 ex/510 em images before (**a**) and after (**b**) stimulation of the cell (*red outline*). *Bottom*: intracellular (IC) Fura2 fluorescence \[I~fura2~\] of primary (*red*) and secondary (*orange*) responders and extracellular (EC) luciferin fluorescence \[I~luciferin~\] (*green*). (**B**) Box plot of \[ATP\]~e~ in pericellular region of stimulated C2-OB, *black markers*: independent observations, n = 13 stimulated cells. (**C**) Correlation between \[ATP\]~e~ and percentage of secondary responders observed in C2-OB (n = 20 stimulated primary responses), *dashed line*: linear regression. Source data for [Figure 2](#fig2){ref-type="fig"} is provided in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.37812.008Figure 2---source data 1.](elife-37812-fig2){#fig2}

Vesicular ATP released upon mechanical stimulation is not the primary source of extracellular ATP {#s2-2}
-------------------------------------------------------------------------------------------------

Vesicular ATP release was proposed to be a major source of extracellular ATP (*5*). Using confocal microscopy, we found that an acidophilic marker quinacrine and a fluorescent ATP analog MANT-ATP co-localized in intracellular granular compartments ([Figure 3A](#fig3){ref-type="fig"}; [Figure 3---video 1](#fig3video1){ref-type="video"}--[2](#fig3video2){ref-type="video"}). Quinacrine-positive vesicular pool was entirely released after treatment with Ca^2+^ ionophore ionomycin, and only partially by mechanical stimulation ([Figure 3B](#fig3){ref-type="fig"}; [Figure 3---video 3](#fig3video3){ref-type="video"}--[5](#fig3video5){ref-type="video"}), while negligible vesicular release was observed in unstimulated cells. Interestingly, vesicular release peaked within 20 s of mechanical stimulation ([Figure 3C, D](#fig3){ref-type="fig"}), while ATP release within \~2 s ([Figure 2A](#fig2){ref-type="fig"}). Basal vesicular density was 70 ± 4×10^−3^ vesicles/µm^2^ ([Figure 3E](#fig3){ref-type="fig"}) and mechanical stimulation resulted in the cumulative release of 5 ± 1×10^−3^ vesicles/µm^2^ over 100 s post-stimulation (7.2 ± 1.2% of the basal vesicular pool) ([Figure 3F](#fig3){ref-type="fig"}). In \[Ca^2+^\]~e~-free conditions vesicular density was unaffected, whereas mechanically evoked vesicular release was markedly suppressed ([Figure 3E, F](#fig3){ref-type="fig"}). Treatment with N-ethylmaleimide (NEM) caused a 33 ± 2% increase in the vesicular density ([Figure 3E](#fig3){ref-type="fig"}), consistent with a NEM-induced increase in the readily releasable vesicular pool ([@bib19]), and a 55 ± 8% increase in mechanically-evoked vesicular exocytosis ([Figure 3F](#fig3){ref-type="fig"}). Surprisingly, the percentage of secondary responders and activation rates for Ca^2+^ responses (response amplitude divided by time for signal to increase from 10 to 90% of peak) were unaffected in \[Ca^2+^\]~e~-free conditions, whereas NEM induced a significant decline in the percentage of secondary responders and activation rates ([Figure 3G, H](#fig3){ref-type="fig"}). We measured bulk ATP release following mechanical stimulation by media displacement, a model for turbulent fluid shear stress (tFSS, [@bib33], [Figure 3I](#fig3){ref-type="fig"}). Proportional to the extent of tFSS, 21 ± 11 to 422 ± 97 amol ATP/cell were released, approaching 31.5% of total intracellular ATP at high tFSS ([Figure 3J](#fig3){ref-type="fig"}). tFSS (10x media displacements) induced release of 324 ± 50 amol ATP/cell, while ionomycin only led to release of 94 ± 5 amol ATP/cell. Moreover, tFSS-induced ATP release was significantly potentiated under \[Ca^2+^\]~e~-free conditions (961 ± 88 amol ATP/cells) and inhibited in NEM-treated cells (41 ± 24 amol ATP/cells) ([Figure 3K](#fig3){ref-type="fig"}). We also investigated conductive channels, however, pharmacological inhibition of Maxi-anion channels, P2X7, Connexins, Pannexins, T-type VSCC, TRPV4 or Piezo1 channels did not affect tFSS-stimulated ATP release ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Although inhibition of L-Type VSCC had a small inhibitory effect ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), our data suggest that conductive channels cannot account for ATP release observed from mechanically stimulated osteoblasts. Importantly, our data show that increases in vesicular release were consistently associated with a reduction in mechanically stimulated ATP release, while inhibition of vesicular exocytosis increased ATP release from mechanically-stimulated osteoblasts.

![Vesicular ATP released upon mechanical stimulation is not the primary source of extracellular ATP.\
(**A**) Confocal images of CB-OB loaded with quinacrine and MANT-ATP, [Figure 3---video 1-2](#fig3){ref-type="fig"}. (**B**) Changes in quinacrine-loaded CB-OB treated with ionomycin (*left*) or stimulated with micropipette (*right*, region of interest in white). (**C**) Vesicular release event in CB-OB (*top*) coincides with a sudden drop in granular quinacrine fluorescence (*bottom*), [Figure 3---video 3-5](#fig3){ref-type="fig"}.(**D**) Kinetics of vesicular release from CB-OB stimulated by micropipette at 0 s, n = 37 stimulated cells. (**E--H**) Quinacrine- (**E, F**) or Fura2- (**G, H**) loaded CB-OB were pre-treated (10 min) with vehicle, ionomycin (iono) or NEM or placed in \[Ca^2+^\]-depleted physiological solution, and micropipette-stimulated when indicated (+). Vesicular density (**E**) and cumulative release (**F**), secondary responsiveness (**G**) and \[Ca^2+^\] response activation rates (**H**) were determined, n = 7--37 primary cells. (**I**) tFSS was applied by replacing 50% media volume *n* times. (**J, K**) ATP released per cell (*left axis*) or as percent of cellular ATP content (*right axis*) was measured following CB-OB stimulation by tFSS (**J**, *black dashed line*: rational function fit; *red dashed line:* corresponding asymptote) or after indicated pre-treatments followed by tFSS (**K**, 10x media displacements, +), n = 6--8 independent cultures. For [Figure 3](#fig3){ref-type="fig"}, means ± SEM, \*significance compared to vehicle (**E--H**), basal ATP release (**J**) or to tFSS-stimulated vehicle (**K**) by ANOVA. Source data for [Figure 3](#fig3){ref-type="fig"} is provided in [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.37812.017Figure 3---source data 1.](elife-37812-fig3){#fig3}

Mechanical stimuli regularly and reversibly compromise the integrity of the osteoblast membrane {#s2-3}
-----------------------------------------------------------------------------------------------

We hypothesized that mechanically stimulated ATP release is related to membrane injury. Adopting a Fura2-based dye-leakage assay ([@bib40]), we examined changes in 340 ex/510 em Fura2 fluorescence following mechanical stimulation of osteoblasts ([Figure 4A](#fig4){ref-type="fig"}). In \~40% of micropipette-stimulated osteoblasts, intracellular Fura2 fluorescence returned to pre-stimulation baseline (minor or no injury; mIn). However, in 30--40% of osteoblasts post-stimulation fluorescence was partially reduced (intermediate injury; iIn) and in 15--20% of osteoblasts completely lost (severe injury; sIn) ([Figure 4B](#fig4){ref-type="fig"}). The extent of injury sustained by a micropipette-stimulated cell correlated with the magnitude and duration of \[Ca^2+^\]~i~ elevations ([Figure 4C--E](#fig4){ref-type="fig"}), as well as the percentage of secondary responders ([Figure 4F](#fig4){ref-type="fig"}), suggesting that ATP release is related to the extent of membrane disruption. In a dye uptake assay, we added membrane impermeable dyes, trypan blue (TB) or rhodamine-conjugate dextran (R-dextran), to osteoblasts before or after mechanical stimulation ([Figure 4G](#fig4){ref-type="fig"}). When the dyes were applied prior to tFSS, the proportion of dye-permeable osteoblasts positively correlated with the degree of tFSS. The extent of dye uptake was higher for TB (\~900 Da) compared to R-dextran (\~10 kDa) ([Figure 4H,I](#fig4){ref-type="fig"}). However, when membrane permeability was examined 300 s after stimulation, a significantly lower percentage of cells were permeable to the dyes ([Figure 4H,I](#fig4){ref-type="fig"}). Hemichannel involvement was excluded, since hemichannel blockers did not affect mechanically-stimulated \[Ca^2+^\]~i~ elevations, membrane permeability or ATP release ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Consistent with transient membrane disruption, lactate dehydrogenase (LDH, \~140 kDa) leaked into the extracellular media proportionally to tFSS magnitude ([Figure 4J](#fig4){ref-type="fig"}), even though cell viability was minimally affected 1 hr after tFSS stimulation ([Figure 4K](#fig4){ref-type="fig"}). Examining TB uptake following micropipette stimulation, we have found that all C2-OB were TB-permeable immediately upon stimulation, decreasing to 75 ± 22% within 10 s, to 40--50% by 180 s and to 18 ± 12% by 300 s ([Figure 4L](#fig4){ref-type="fig"}). Comparing these data to dye leakage experiments suggested that minor injuries resealed within 10 s, intermediate injuries within 20--180 s and severe injuries did not reseal by 300 s. ([Figure 4L](#fig4){ref-type="fig"}). Based on predicted molecular radii of the dyes ([@bib9]), we estimated the membrane lesion radius to be on the nanometer scale, sufficiently large to permit the efflux of smaller ATP molecules (\~507 Da) ([Figure 4M](#fig4){ref-type="fig"}).

![Mechanical stimuli regularly and reversibly compromise the integrity of osteoblast cell membrane.\
(**A--F**) Membrane permeability in micropipette-stimulated Fura2-loaded osteoblasts. (**A**) *Top:* Schematic of dye-leakage assay. *Bottom*: 340 ex/510 em before (**a**) and after (**b**) CB-OB stimulation (*white outline)*. (**B**) Representative Fura2 traces in C2-OB with minor (mIn), intermediate (iIn) or severe (sIn) cell injury and relative occurrence frequency (*right*, n = 35--40 stimulated cells). (**C**) C2-OB \[Ca^2+^\]~i~ responses and differences (*inset*) for mIn (*green*), iIn (*orange*) and sIn (*red*), n = 8--14 stimulated cells. (**D--F**) Primary \[Ca^2+^\]~i~ response amplitudes (**D**) and decay constants (**E**), and secondary responsiveness (**F**) in CB-OB (*black*; n = 40 stimulated cells) or C2-OB (*white*; n = 35 stimulated cells), grouped by cell injury status. (**G--K**) Membrane permeability in tFSS-stimulated osteoblasts. (**G**) *Top:* schematic of dye-uptake assay. *Bottom*: CB-OB stained with TB (*top*) or R-dextran (*bottom*) prior to (0 s, *left*) or after (300 s, *right*) tFSS application (10x). Uptake of TB (**H**) or R-dextran (**I**) added prior to (0 s) or after (300 s) tFSS stimulation of CB-OB (n = 4 independent cultures). (**J**) Leakage of LDH from CB-OB 5 min after tFSS (n = 8 independent cultures, normalized to total LDH). (**K**) Viability of C2-OB 1 hr after tFSS assessed by alamarBlue (n = 8--16 independent cultures). (**L**) Uptake of TB added at indicated times after micropipette-stimulation of C2-OB (**L-a**, n = 4--23 stimulated cells) compared to relative frequencies of mIn, iIn and sIn assessed by Fura2-leakage assay (**L-b**). (**M**) Calculated minimum membrane lesion radius R~min~ required for permeability to LDH, R-dextran, TB, Fura2 and ATP. For [Figure 4](#fig4){ref-type="fig"}, means ± SEM, *dashed lines*: linear regression, \*significance by ANOVA. Source data for [Figure 4](#fig4){ref-type="fig"} is provided in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.37812.020Figure 4---source data 1.](elife-37812-fig4){#fig4}

Osteocyte membranes are reversibly disrupted during mouse *in vivo* tibia loading {#s2-4}
---------------------------------------------------------------------------------

To determine whether mechanically induced repairable membrane disruptions occur *in vivo*, 10-week-old female C57Bl/6J mice were injected with lysine-fixable Texas Red-conjugated dextran (LFTR-Dex, \~10 kDa) either 30 min prior to or 20 min after cyclic compressive tibial loading to strain magnitudes at the upper level of physiological activities (600 µε) or at supraphysiological osteogenic levels (1200 µε) ([@bib43]) ([Figure 5A--D](#fig5){ref-type="fig"}, [Figure 5-video 1](#fig5video1){ref-type="video"}). In the contralateral non-loaded control tibiae (which experienced habitual loads only), sclerostin-positive osteocytes were observed at a density of 3212 ± 287 cells/mm^2^ ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}),\~4--7% of which demonstrated LFTR-Dex uptake, while only 2% of calvarial osteocytes were LFTR-Dex positive ([Figure 5E](#fig5){ref-type="fig"}). Cyclic compressive tibial loading in the presence of LFTR-Dex resulted in significantly increased osteocyte dye uptake compared to unloaded bone, demonstrating that *in vivo* mechanical loading results in cellular membrane disruption ([Figure 5F,G](#fig5){ref-type="fig"}, *red*). Importantly, when LFTR-Dex was administered 20--50 min after 600 µε loading, the levels of cellular dye uptakes were similar to those in unloaded tibia, suggesting that damage evident immediately after loading was repaired within this time period ([Figure 5F](#fig5){ref-type="fig"}*, light blue*). Of interest, when LFTR-Dex was administered 20--50 min after 1200 µε loading, the proportion of osteocyte exhibiting dye uptake was significantly lower compared to non-loaded controls, suggesting that adaptive improvements in membrane integrity occurred in response to the supraphysiological strain ([Figure 5F,G](#fig5){ref-type="fig"}, *dark blue*).

![Osteocyte membranes are reversibly disrupted during *in vivo* cyclic compressive loading of the tibia.\
(**A, B**) Left tibia of anesthetized mouse was positioned in loading device as shown in picture (**A**) and schematic (**B**). *Arrows* indicate direction of load. (**C**) The triangle waveform included 0.15 s symmetric active loading/unloading, with a 0.1 s rest phase (−1 N) between load cycles and a 5 s rest inserted between every four cycles. A maximum force of −5.5 N or −11 N was applied, which engenders 600 µε or 1200 µε, respectively at the periosteal surface of the tibia mid-diaphysis in these mice. (**D**) Experimental design schematic: animals were injected with LFTR-Dex 30 min before (*red*) or 20 min after (*blue*) *in vivo* cyclic tibial loading (5 min). (**E**) Proportion of cells exhibiting LFTR-Dex uptake in calvariae (n = 5 animals) and control tibiae (n = 20 from 10 animals), normalized to average total cell number, means ± SEM, \*\*p\<0.01. (**F**) Dye uptake in tibia injected before (*red*) or after (*blue*) loading at 600 µε or 1200 µε, means ± SEM, n = 5/strain/dye protocol, normalized to non-loaded contralateral tibia, \*significance compared to non-loaded tibia, ^††^significance between dye protocols, by ANOVA. (**G**) Contrast enhanced images of dye uptake in control (*left*), and 1200 µε loaded tibia injected with dye before (*middle*) or after (*right*) loading. Source data for [Figure 5](#fig5){ref-type="fig"} is provided in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.37812.023Figure 5---source data 1.](elife-37812-fig5){#fig5}

PKC regulates vesicular exocytosis and membrane resealing {#s2-5}
---------------------------------------------------------

Vesicular exocytosis has been demonstrated to facilitate membrane repair and improve membrane integrity in a PKC-dependent manner ([@bib40]). We examined the role of Ca^2+^/PLC/PKC pathway during mechanically induced membrane injury and resealing. Pharmacological activation of PKC ([Figure 6A](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}) and NEM-induced potentiation of vesicular release ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}) both attenuated tFSS-induced membrane disruption. Depletion of \[Ca^2+^\]~e~, or pharmacological inhibition of PLC ([Figure 6---figure supplement 2A,B](#fig6s2){ref-type="fig"}) or PKC ([Figure 6A,B](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}) increased membrane disruption in osteoblasts following tFSS or micropipette stimulation. Together these findings suggest that membrane repair was regulated by extracellular calcium influx, PLC/PKC signaling and vesicular exocytosis. We next investigated the link between Ca^2+^/PLC/PKC pathway and mechanically stimulated \[Ca^2+^\]~i~ elevations, vesicular exocytosis and ATP release. Depletion of \[Ca^2+^\]~e~ or PLC inhibition consistently reduced the amplitude of mechanically-stimulated \[Ca^2+^\]~i~ elevations ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}) and vesicular release ([Figure 6---figure supplement 2D](#fig6s2){ref-type="fig"}), and potentiated ATP release ([Figure 6---figure supplement 2E](#fig6s2){ref-type="fig"}). PKC activation had minor effect on calcium responses ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}), augmented vesicular release ([Figure 6C](#fig6){ref-type="fig"}) and reduced ATP release ([Figure 6D](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). In contrast, PKC inhibition potentiated calcium responses ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}), suppressed vesicular release ([Figure 6C](#fig6){ref-type="fig"}) and increased ATP release ([Figure 6D](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). PMA-induced PKC activation rescued vesicle pool depletion following PLC inhibition, thereby positioning PKC signaling downstream of PLC ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). Together these data suggest that mechanically stimulated membrane injury and repair, vesicular release and ATP release are regulated by Ca^2+^/PLC/PKC-dependent signaling.

![Membrane resealing depends on PKC-regulated vesicular exocytosis.\
(**A--D**) CB-OB were pretreated with vehicle, PMA or Bis, and membrane injury (**A, B**) vesicular exocytosis (**C**) and ATP release (**D**) were assessed. (**A**) TB uptake at 0 and 300 s after tFSS (10x), n = 5--8 independent cultures. (**B**) Fura2 leakage, determined as percentage of sIn cells after micropipette-stimulation, n = 9--16 stimulated cells. (**C**) Cumulative vesicular release over 100 s after micropipette-stimulation, n = 6--10 stimulated cells. (**D**) ATP release over 60 s following 10x tFSS stimulation, n = 8 independent cultures. (**E**) Immunoblotting for PKC isoform phosphorylation in CB-OB treated with vehicle, PMA or Bis (30 min); or 30 s, 90 s or 300 s after tFSS (10x). Shown are immunoblots (*left*), complete gels in [Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}, and densitometry (*right*) of phosphorylated and total conventional (pPKC pan), atypical (pPKC ζ/λ), novel (pPKC δ/θ), and PKD/PKCµ isoforms. Phosphorylated PKC isoforms were normalized by total PKC levels and reported relative to vehicle, n = 3 independent cultures. (**F--H**) Relationships between vesicular release (pooled data from vesicular release experiments), membrane disruption (pooled from membrane integrity experiments) and ATP release (pooled from 10x tFSS experiments) following mechanical stimulation of CB-OB, *solid line* - regression. For [Figure 6](#fig6){ref-type="fig"}, data are means ± SEM, \*significance compared to vehicle (0 s vehicle for A), ^†^significance compared to 300 s vehicle (**A**) and ^\#^significance of indicated comparisons (**A**), by ANOVA or by regression. Source data for [Figure 6](#fig6){ref-type="fig"} is provided in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.37812.032Figure 6---source data 1.](elife-37812-fig6){#fig6}

We next examined which PKC isoform is involved in the mechanoresponse. Immunoblot analysis demonstrated that mechanical stimulation (using tFSS) of CB-OB activated conventional PKCα/β and PKD/PKCμ, but not atypical PKCζ/λ or novel PKCδ/θ isoforms ([Figure 6E](#fig6){ref-type="fig"}, [Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}). PMA stimulated phosphorylation of conventional and PKD/PKCμ isoforms, but not atypical or novel PKC isoforms, while only basal PKD/PKCμ phosphorylation had a tendency (p=0.09) to be inhibited by Bis. Total PKC levels were unaffected by pharmacological interventions or mechanical stimulation ([Figure 6---figure supplement 4G](#fig6s4){ref-type="fig"}). These findings suggest that the PKD/PKCμ isoform regulates membrane resealing in osteoblasts.

To establish the relationship between vesicular release, membrane disruption and ATP release, we pooled data for the mechanically induced responses from all treatments studied in CB-OB ([Figure 6F--H](#fig6){ref-type="fig"}). Mechanically induced vesicular release negatively correlated with the extent of membrane disruption ([Figure 6F](#fig6){ref-type="fig"}) and the amount of ATP released ([Figure 6G](#fig6){ref-type="fig"}), while membrane disruption positively correlated with amount of ATP released in response to mechanical stimulation ([Figure 6H](#fig6){ref-type="fig"}). These data support a model in which mechanical disruption of the cell membrane leads to ATP spillage, while the extent of membrane resealing, regulated by Ca^2+^/PLC/PKC-dependent vesicular exocytosis, limits the amount of total ATP released ([Figure 7](#fig7){ref-type="fig"}).

![Proposed model for mechanically stimulated ATP release in osteoblasts.\
***Resting Osteoblasts***: Under basal conditions, the cell membrane is intact and intracellular free calcium levels and PLC/PKC signaling are minimal. ***Mechanical injury***: Mechanical stimulation results in disruption of the cellular membrane, which leads to the influx of calcium, activation of PLC/PKC signalling, and the efflux of ATP. ***Membrane repair***: The disrupted membrane is rapidly repaired through a process involving Ca^2+^/PLC/PKC-dependent vesicular exocytosis, thereby limiting ATP release. ***Cellular adaptation***: Elevated PKC levels result in priming of the vesicular pathway, likely regulating cellular resilience and responsiveness to subsequence cycles of mechanical stimulation.](elife-37812-fig7){#fig7}

Discussion {#s3}
==========

This study establishes a novel mechanism of mechanotransduction in bone cells, which positions ATP release as the integrated outcome of membrane injury (reflective of the destructive potential of mechanical forces) and membrane repair (countering and adapting to the damage). We report that mechanical stimuli *in vitro* and *in vivo* induced reversible cell membrane disruption. This disruption resulted in ATP release predominantly through the compromised membrane, rather than through vesicular or conductive mechanisms. Ca^2+^/PLC/PKC-dependent vesicular release was necessary for successful membrane repair and prevention of further ATP release. Importantly, prior activation of PKD/PKCµ or vesicular priming improved membrane integrity and repair, thereby minimizing membrane injury and ATP release upon subsequent mechanical stimulation, and serving as a mechanism of cellular mechano-adaptive memory.

Membrane injury {#s3-1}
---------------

We have demonstrated that non-lethal cell membrane injury is routine in mechanically stimulated cells. *In vitro*, single cell membrane deformation or fluid shear stress transiently compromised cell membrane integrity in 2--30% of cells, which was repaired within 10--100 s. Consistent with findings observed using *in vitro* models of mechanical stimulation, *in vivo* cyclic compressive tibial loading engendering physiological and supraphysiological strains resulted in transient osteocyte membrane disruption in 5--10% of cells. Interestingly, supraphysiological mechanical strains improved membrane integrity post-stimulation compared to baseline levels. Previously, non-lethal reversible cell wounding was shown to occur in mechanically active tissues, with membrane-impermeable marker uptake reported in 3--20% of cells in skeletal muscle, 3--6% in skin, 25% in cardiac muscle, 2--30% in lung and aorta ([@bib23]). Consistent with our findings, membrane disruption was reported in 20--60% of long bone osteocytes after *in vivo* treadmill loading ([@bib44]). The higher prevalence of disruption reported by Yu et al. in long bones was likely a consequence of cumulative tracer uptake over 18 hr ([@bib44]), while our study examined membrane disruption over a 20--50 min period. Our data demonstrated that reparable membrane injuries are common and significantly contribute to ATP release from mechanically stimulated osteoblasts and osteocytes.

ATP release {#s3-2}
-----------

We observed that osteoblasts release 70 ± 24 amol ATP/cell in response to direct membrane deformation and 21 ± 11 to 422 ± 97 amol ATP/cell in response to tFSS, which is consistent with previously reported estimates ranging from 24 ± 1 to 324 ± 59 amol ATP/cell ([@bib10]; [@bib41]; [@bib16]; [@bib15]; [@bib11]; [@bib29]; [@bib32]; [@bib22]). Osteoblasts have been reported to release ATP through mechanisms related to vesicular exocytosis ([@bib10]; [@bib32]) and L-type VSCC ([@bib10]). In osteocytes, hemichannels ([@bib16]; [@bib35]), P2X7 ([@bib35]) and T-type VSCC ([@bib38]) have also been implicated. We visualized ATP-containing quinacrine-positive vesicles and directly demonstrated their release upon mechanical stimulation. Surprisingly, the total vesicular ATP content was \~94 ± 5 amol ATP/cell, which, considering that only 7.2 ± 1.2% of vesicles were released upon mechanical stimulation, is much less (\<10 amol ATP/cell) than mechanically induced ATP release. Moreover, treatments that potentiated vesicular release resulted in a surprising decrease in ATP release, while treatments interfering with vesicular release enhanced ATP release. In search for an alternative route of ATP release, we found that mechanically stimulated ATP release was proportional to the extent of membrane injury.

Membrane resealing {#s3-3}
------------------

Vesicular exocytosis is believed to promote membrane repair via membrane insertion, thereby reducing membrane tension and allowing exposed hydrophobic residues to reseal ([@bib23]). We have shown that vesicular release was critical for the repair of mechanically induced membrane injury and that the Ca^2+^/PLC/PKC pathway regulates vesicular exocytosis in osteoblasts. We interrogated the role of vesicular release in the mechanoresponse using NEM, a modulator of vesicular docking machinery ([@bib19]). While NEM is commonly used as an inhibitor of vesicular release ([@bib10]; [@bib14]), it has also been shown to increase vesicular release probability ([@bib13]) through accumulation of readily-releasable vesicles ([@bib19]). Using real-time imaging, we demonstrated that NEM increased the basal vesicular density and potentiated mechanically stimulated vesicular exocytosis in osteoblasts. In the presence of NEM, mechanically induced membrane injury and ATP release were significantly reduced. Vesicular exocytosis has been implicated as a mechanism of ATP release from osteoblasts and osteocytes ([@bib10]; [@bib16]; [@bib32]) based on the assumed inhibition of vesicular exocytosis by NEM or vesicular trafficking by brefeldin A, bafilomycin or monensin. However, our data demonstrated that the role of vesicles cannot be inferred without a direct validation of the effect of NEM on vesicular release. In our study, \[Ca^2+^\]~e~ depletion abolished mechanically stimulated vesicular release, interfered with membrane repair and increased ATP release. Calcium is one of the first mechanically induced signals that initiates downstream responses ([@bib30]), including exocytosis-mediated membrane repair ([@bib6]). It was previously shown that during *in vivo* loading of mouse bone, the number of osteocytes exhibiting \[Ca^2+^\]~i~ elevations increased proportionally to the magnitude of applied strain ([@bib17]). We found that PLC and PKCµ, known downstream targets of Ca^2+^ signaling ([@bib25]), regulated basal vesicle abundance and membrane resealing. Our study suggests that the osteoporotic phenotype reported in PKCµ-deficient bones ([@bib18]) may be associated with defective mechanoresponsiveness. Consistent with mechanisms of facilitated membrane resealing ([@bib40]; [@bib6]), we propose that mechanical stimulation results in membrane disruption, which leads to ATP efflux and Ca^2+^ influx, triggering vesicular exocytosis and membrane repair that then limits ATP release ([Figure 7](#fig7){ref-type="fig"}).

Mechano-adaptive memory {#s3-4}
-----------------------

Our findings suggest that osteoblast mechano-adaptive status may be influenced by PKCµ/vesicular signaling. Activation of PKC prior to mechanical stimulation or priming the vesicular pool for release with NEM resulted in drastic decreases in membrane injury and ATP release in response to subsequent mechanical stimulation. Prior work has demonstrated that mechanical loading induces the production and release of LAMP-1-positive vesicles from osteocytes (LAMP-1 colocalizes with the quinacrine tracer-dye used in this study ([@bib4]), which was critical for mechano-adaptive bone formation ([@bib26]). This mechano-adaptive effect may underlie cellular accommodation in the bone response to mechanical loading previously reported ([@bib34]), and explain the reduced responsiveness of osteocytes exposed to higher frequency *in vivo* mechanical loading, compared to lower frequency loading of the same magnitude ([@bib17]). Our findings suggest that during repeated mechanical stimulation, the priming of PKCµ/vesicular pathway by earlier stimuli will determine osteoblast resilience and responsiveness to subsequent cycles of mechanical stimulation, representing a mechanism for cellular accommodation.

Concluding remarks {#s3-5}
------------------

In this study, we established the regulatory mechanisms involved in controlling the amount of ATP released following reversible cellular injury. We have demonstrated that membrane injury and repair are common under physiological stresses *in vitro* and *in vivo*, and determined the critical role for PKC-regulated vesicular exocytosis in bone cell membrane repair. We suggest that rather than delivering ATP to extracellular space, exocytosis of ATP-containing vesicles limits the much larger efflux of intracellular ATP through damaged membranes. We propose a model of biological adaptation to mechanical forces, which directly links mechanosensation through reversible membrane injury and ATP release to the development of adaptive resilience against the destructive potential of mechanical forces. PKC-mediated vesicular release provides a target for potential therapeutic interventions to modulate mechano-responsiveness and mechano-resilience in humans habitually experiencing altered mechanical environment, such as astronauts or paralysis patients.

Materials and methods {#s4}
=====================

All procedures were approved by McGill's University's Animal Care Committee (protocols \# 2012--7127 and 2016--7821) and complied with the ethical guidelines of the Canadian Council on Animal Care.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                Designation                   Source or reference        Identifiers                                                                 Additional\
  (species) or resource                                                                                                                                             information
  ---------------------------- ----------------------------- -------------------------- --------------------------------------------------------------------------- --------------------------------------------
  Cell line\                   BMP2-transfected C2C12\       Dr. M. Murshed,\                                                                                       osteoblast cell line
  (*M. musculus*)              myoblast cells\               McGill University                                                                                      
                               (C2C12-BMP2; C2-OB)                                                                                                                  

  Strain, strain background\   10 week-old C57Bl/6J          Jackson Laboratory         Stock \#: 000664;\                                                          primary osteoblast source,\
  (*M.musculus*, female)                                                                RRID: [IMSR_JAX:000644](https://scicrunch.org/resolver/IMSR_JAX:000644)\    *in vivo* studies
                                                                                        \                                                                           

  Software,\                   Calcium\                      DOI: 10.3389/\                                                                                         MATLAB algorithm\
  algorithm                    Analyser                      fphys.2016.00525                                                                                       for calcium analysis

  Chemical compound, drug      MANT-ATP                      AnaSpec                    Cat. AS-64610                                                               fluorescent ATP analog,\
                                                                                                                                                                    5 µM (overnight, 37°C)

  Chemical compound, drug      GsMTx-4; GsM                  Alomone Labs               Cat. STG-100                                                                Piezo1 inhibitor,\
                                                                                                                                                                    1 µM (10 min,\
                                                                                                                                                                    room temperature)

  Chemical compound, drug      U73122; U73                   Calbiochem                 Cat. 662035                                                                 PLC inhibitor,\
                                                                                                                                                                    10 µM (10 min,\
                                                                                                                                                                    room temperature)

  Antibody                     GAPDH (D16H11,\               Cell Signaling\            Cat. 5174; RRID:[AB_10622025](https://scicrunch.org/resolver/AB_10622025)   WB, 1:1000 dilution,\
                               Rabbit antibody)              Technology                                                                                             5% BSA/TBST\
                                                                                                                                                                    (1 hr, room temperature)

  Antibody                     β-tubulin (9F3,\              Cell Signaling\            Cat. 2128; RRID:[AB_823664](https://scicrunch.org/resolver/AB_823664)       WB, 1:1000 dilution, 5% BSA/TBST\
                               Rabbit antibody)              Technology                                                                                             (1 hr, room temperature)

  Antibody                     p-PKC (pan; βII Ser660,\      Cell Signaling\            Cat. 9371; RRID:[AB_330848](https://scicrunch.org/resolver/AB_330848)       WB, 1:1000 dilution, 5% BSA/TBST\
                               \                             Technology                                                                                             (over night, 4°C)
                               Rabbit antibody)                                                                                                                     

  Antibody                     PKCα\                         Cell Signaling\            Cat. 2056; RRID:[AB_2284227](https://scicrunch.org/resolver/AB_2284227)     WB, 1:1000 dilution,5% BSA/TBST\
                               (Rabbit antibody)             Technology                                                                                             (over night, 4°C)

  Antibody                     p-PKCδ/θ\                     Cell Signaling\            Cat. 9376; RRID:[AB_330848](https://scicrunch.org/resolver/AB_330848)       WB, 1:1000 dilution,\
                               (Ser643/676,\                 Technology                                                                                             5% BSA/TBST\
                               Rabbit antibody)                                                                                                                     (over night, 4°C)

  Antibody                     PKCδ (D10E2, Rabbit\          Cell Signaling\            Cat. 9616; RRID:[AB_10949973](https://scicrunch.org/resolver/AB_10949973)   WB, 1:1000 dilution,\
                               anitbody)                     Technology                                                                                             5% BSA/TBST\
                                                                                                                                                                    (over night, 4°C)

  Antibody                     p-PKD/PKCµ\                   Cell Signaling\            Cat. 2054; RRID:[AB_330848](https://scicrunch.org/resolver/AB_330848)       WB, 1:1000 dilution,\
                               (Ser744/748,\                 Technology                                                                                             5% BSA/TBST\
                               Rabbit antibody)                                                                                                                     (over night, 4°C)

  Antibody                     PKD/PKCµ (D4J1N,\             Cell Signaling\            Cat. 90039                                                                  WB, 1:1000 dilution,\
                               Rabbit antibody)              Technology                                                                                             5% BSA/TBST\
                                                                                                                                                                    (over night, 4°C)

  Antibody                     p-PKCζ/λ (Thr410/403,\        Cell Signaling\            Cat. 9378; RRID:[AB_330848](https://scicrunch.org/resolver/AB_330848)       WB, 1:1000 dilution,\
                               Rabbit antibody)              Technology                                                                                             5% BSA/TBST\
                                                                                                                                                                    (over night, 4°C)

  Antibody                     PKCζ (C24E6,\                 Cell Signaling\            Cat. 9368;\                                                                 WB, 1:1000 dilution,\
                               Rabbit antibody)              Technology                 RRID:[AB_10693777](https://scicrunch.org/resolver/AB_10693777)              5% BSA/TBST\
                                                                                                                                                                    (over night, 4°C)

  Antibody                     anti-rabbit IgG,\             Cell Signaling\            Cat. 7074;\                                                                 WB, 1:1000 dilution,\
                               HRP-linked\                   Technology                 RRID:[AB_2099233](https://scicrunch.org/resolver/AB_2099233)                5% BSA/TBST\
                               secondary antibody)                                                                                                                  (1 hr, room temperature)

  Chemical compound, drug      Minimum Essential Medium\     Gibco                      Cat. 12,000--022                                                            cell culture\
                               (MEM) α; αMEM                                                                                                                        reagent

  Chemical compound, drug      Trypan Blue Solution,\        Gibco                      Cat. 15250061                                                               *in vitro* injury\
                               0.4%; TB                                                                                                                             assay dye

  Commercial assay or kit      Alamar Blue Cell\             Invitrogen                 Cat. DAL1025                                                                cell viability assay
                               Viability Reagent                                                                                                                    

  Chemical compound, drug      DAPI                          Invitrogen                 Cat. D1306;\                                                                IF, nucleur stain, 1:5000 dilution, H~2~0\
                                                                                        RRID:[AB_2629482](https://scicrunch.org/resolver/AB_2629482)                (5 min, room temperature)

  Chemical compound, drug      Fura2 AM                      Invitrogen                 Cat. F1221                                                                  ratiometric calcium-binding dye\
                                                                                                                                                                    (30 min, room temperature)

  Chemical compound, drug      D-Luciferin\                  Invitrogen                 Cat. L2916                                                                  luciferase substrate,\
                               potassium salt                                                                                                                       ATP bioluminescence assay

  Chemical compound, drug      Lucifer Yellow\               Invitrogen                 Cat. L453                                                                   GAP junction permeable dye,\
                               CH, Lithium Salt; LY                                                                                                                 10 µM (2 min, 37°C)

  Chemical compound, drug      Rhodamine\                    Invitrogen                 Cat. D1824                                                                  *in vitro* injury assay dye
                               B-conjugated\                                                                                                                        
                               10 000 MW Dextran;\                                                                                                                  
                               R-dextran                                                                                                                            

  Chemical compound, drug      lysine-fixable Texas\         Invitrogen                 Cat. D1863                                                                  *in vivo* injury assay dye
                               Red-conjugated\                                                                                                                      
                               10 000 MW Dextra; LFTR-Dex                                                                                                           

  Antibody                     Sclerostin (Goat antibody)    R and D Systems            Cat. AF1589;\                                                               IF, 1:1000 dilution,\
                                                                                        RRID:[AB_2195345](https://scicrunch.org/resolver/AB_2195345)                5% BSA/TBST\
                                                                                                                                                                    (over night, 4°C)

  Chemical compound, drug      Collagenase P from\           Roche                      Cat. 11213857001                                                            enzymatic digest of\
                               *Clostridium histolyticum*                                                                                                           bone fragments

  Commercial assay or kit      Cytotoxicity Detection\       Roche                      Cat. 04 744 926 011                                                         LDH leakage assay
                               Kit^PLUS^; LDH                                                                                                                       

  Antibody                     Donkey anti-goat\             Santa Cruz                 Cat. Sc-2024;\                                                              IF, 1:1000 dilution,5% BSA/TBST\
                               IgG-FITC                                                 RRID:[AB_631727](https://scicrunch.org/resolver/AB_631727)                  (1 hr, room temperature)

  Chemical compound, drug      Adenosine 5'-triphosphate\    Sigma-Aldrich              Cat. A9187                                                                  
                               magnesium salt; ATP                                                                                                                  

  Chemical compound, drug      Bisindolylmaleimide II; Bis   Sigma-Aldrich              Cat. B3056                                                                  PKC inhibitor, 1 µM\
                                                                                                                                                                    (10 min, room temperature)

  Chemical compound, drug      Carbenoxolone\                Sigma-Aldrich              Cat. C4790                                                                  Hemichannel blocker, 10 µM\
                               disodium salt; Cbx                                                                                                                   (10 min, room temperature)

  Chemical compound, drug      Fast Red Violet LB Salt       Sigma-Aldrich              Cat. F3381                                                                  alkaline phosphatase\
                                                                                                                                                                    assay reagent

  Chemical compound, drug      Gadolinium (III)\             Sigma-Aldrich              Cat. 439770                                                                 Mechanically-sensitive channel\
                               chloride; Gd^3+^                                                                                                                     blocker, 10 µM\
                                                                                                                                                                    (10 min, room temperature)

  Chemical compound, drug      GSK2193874; GSK               Sigma-Aldrich              Cat. SML0942                                                                TRPV4 inhibitor,\
                                                                                                                                                                    100 nM (10 min, room\
                                                                                                                                                                    temperature)

  Chemical compound, drug      HC-067047; HC                 Sigma-Aldrich              Cat. SML0143                                                                TRPV4 inhibitor,100 nM\
                                                                                                                                                                    (10 min,\
                                                                                                                                                                    room temperature)

  Chemical compound, drug      L-ascorbic acid\              Sigma-Aldrich              Cat. A8960                                                                  osteoblast differentiation\
                               2-phosphate\                                                                                                                         reagent,50 µg/mL
                               sesquimagnesium\                                                                                                                     
                               salt hydrate                                                                                                                         

  Chemical compound, drug      Luciferase from\              Sigma-Aldrich              Cat. L9420                                                                  ATP bioluminescence\
                               *Photinus pyralis*                                                                                                                   assay reagent

  Chemical compound, drug      ML218; ML                     Sigma-Aldrich              Cat. SML0385                                                                \
                                                                                                                                                                    T-type VSCC inhibitor,\
                                                                                                                                                                    10 µM (10 min, room temperature)

  Chemical compound, drug      Naphthol\                     Sigma-Aldrich              Cat. N5000                                                                  alkaline phosphatase\
                               AS-MX phosphate\                                                                                                                     assay reagent
                               disodium salt                                                                                                                        

  Chemical compound, drug      N-ethylmaleimide; NEM         Sigma-Aldrich              Cat. E3876                                                                  Vesicular activator,\
                                                                                                                                                                    1 mM (10 min, room\
                                                                                                                                                                    temperature)

  Chemical compound, drug      Nifedipine; Nif               Sigma-Aldrich              Cat. N7634                                                                  L-type VSCC inhibitor,\
                                                                                                                                                                    10 µM\
                                                                                                                                                                    (10 min, room temperature)

  Chemical compound, drug      1-octanol; Oct                Sigma-Aldrich              Cat. 297877                                                                 Connexin blocker,\
                                                                                                                                                                    1 mM (10 min,\
                                                                                                                                                                    room temperature)

  Chemical\                    phorbol\                      Sigma-Aldrich              Cat. P8139                                                                  PKC activator,\
  compound, drug               12-myristate 13-acetate;\                                                                                                            100 nM (10 min,\
                               PMA                                                                                                                                  room temperature)

  Chemical compound, drug      Quinacrine\                   Sigma-Aldrich              Cat. Q3251                                                                  Vesicle dye,\
                               dihydrochloride                                                                                                                      10 µM (15 min,\
                                                                                                                                                                    room temperature)

  Chemical\                    Flufenamic\                   Tocris Bioscience          Cat. 4522                                                                   Hemichannel blocker,\
  compound, drug               Acid; FFA                                                                                                                            10 µM (10 min,\
                                                                                                                                                                    room temperature)

  Chemical compound, drug      Ionomycin calcium\            Tocris Bioscience          Cat. 1704                                                                   calcium ionophore, 100 µM
                               salt; Iono                                                                                                                           

  Chemical compound, drug      PPADS tetrasodium\            Tocris Bioscience          Cat. 0625                                                                   P2R inhibitor,100 µM (10 min,\
                               salt; PPADS                                                                                                                          room temperature)

  Chemical compound, drug      Suramin hexasodium\           Tocris Bioscience          Cat. 1472                                                                   P2R inhibitor, 100 µM (10 min,\
                               salt; Sur                                                                                                                            room temperature)

  Chemical compound, drug      A 740003; A7                  Tocris Bioscience          Cat. 3701                                                                   P2X7 inhibitor, 1 µM (10 min,\
                                                                                                                                                                    room temperature)

  Chemical compound, drug      Dulbecco's Modified\          Wisent Bio Products        Cat. 319--020 CL                                                            cell culture reagent
                               Eagle Medium; DMEM                                                                                                                   

  Chemical compound, drug      Fetal bovine\                 Wisent Bio Products        Cat. 080152                                                                 cell culture reagent
                               Serum; FBS                                                                                                                           

  Chemical compound, drug      Penicillin\                   Wisent Bio\                Cat. 450--201-EL                                                            antibiotic, 1%
                               Streptomycin                  Products                                                                                               

  Chemical compound, drug      Sodium Pyruvate               Wisent Bio\                Cat. 600--110 UL                                                            cell culture reagent
                                                             Products                                                                                               

  Chemical compound, drug      Collagenase Type II           Worthington Biochemical\   Cat. LS004176                                                               enzymatic digest\
                                                             Corporation                                                                                            of bone fragments
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Solutions {#s4-1}
---------

Phosphate-buffered saline (PBS; 140 mM NaCl, 3 mM KCl, 10 mM Na~2~HPO~4~, 2 mM KH~2~PO~4~, pH 7.4), sterilized by autoclave. Physiological solution (PS; 130 mM NaCl; 5 mM KCl; 1 mM MgCl~2~; 1 mM CaCl~2~; 10 mM glucose; 20 mM HEPES, pH 7.6), sterilized by 0.22 µM filtration. In \[Ca^2+^\]-free physiological solution, CaCl~2~ was excluded and 10 mM EGTA was added to chelate any residual calcium, sterilized by 0.22 µm filtration. Bioluminescence reaction buffer (0.1 M DTT, 25 mM tricine, 5 mM MgSO~4~, 0.1 mM EDTA, 0.1 mM NaN~3~, pH 7.8), sterilized by 0.22 µm filtration. RIPA lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA, 1 mg/mL aprotinin, 2 mg/mL leupeptin, 0.1 mM phenylmethylsulfonyl fluoride, 20 mM NaF, 0.5 mM Na~3~VO~4~). TBST buffer (10 mM Tris-HCL, pH 7.5, 150 mM NaCl, 1% Tween 20).

Pharmacological interventions {#s4-2}
-----------------------------

The pharmacological interventions (final concentration, name (***abbreviation***): molecular target) used in this study were: 10 µM Gadolinium (***Gd^3+^***): maxi-anion channel, 10 µM Carbenoxolone (***Cbx***): connexins/pannexins, 10 µM Flufenamic Acid (***FFA***): connexins, 1 mM 1-Octanol (***Oct***): connexins, 100 nM GSK 2193874 (***GSK***): TRPV4, 100 nM HC 067047 (***HC***): TRPV4, 10 µM Nifedipine (***Nif***): L-type VSCC, 10 µM ML218 (***ML***): T-type VSCC, 100 µM Suramin (***Sur***): P2 receptors (P2R), 100 µM ***PPADS***: P2 receptors, 1 µM A740003 (***A7***): P2X7 receptor, 10 µM U73122 (***U73***): PLC, 100 nM Phorbol 12-myristate 13-acetate (***PMA***): PKC, 1 µM Bisindolylmaleimide II (***Bis***): PKC, 1 mM N-Ethylmaleimide (***NEM***): NSF, 1 µM GsMTx-4 (***GsM***): Piezo1. Unless stated otherwise, cells were treated with drugs for 10 mins prior to experiments. We validated the effects of hemichannel blockers ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) and evaluated the effects of the inhibitors on ATP- or citrate-induced \[Ca^2+^\]~i~ responses in Fura2-loaded C2-OB cells and on luciferin/luciferase bioluminescence ([Figure 6---figure supplement 5](#fig6s5){ref-type="fig"}).

Cell cultures {#s4-3}
-------------

Three osteoblast models were used in this study. All key experiments required to support our proposed model were performed using primary CB-OB cells; however, additional data from another primary source (bone-marrow-derived; BM-OB) and cell-line (C2-OB) were reported to emphasize the validity of our findings and demonstrate how different osteoblast models perform in this study.

### Bone-marrow-derived osteoblasts (BM-OB) {#s4-3-1}

To obtain bone-marrow-derived osteoblasts, 4-6 week C57Bl/6J mice were sacrificed and femur and tibia were collected. Bone pieces were sterilized in 70% EtOH and washed (3x, PBS). Bones were cut in half and placed into longitudinally-cut 1 mL pipette tips, with the exposed marrow end of the bone facing down. Pipette tips were centrifuged in Eppendorf tubes at 12 000 rpm (3x, 30 s) to isolate bone marrow cells. Bone marrow cells were plated at a density of 5×10^4^ cells per cm^2^ in osteoblastic differentiation medium (αMEM supplemented with 10% FBS, 1% sodium pyruvate, 1% penicillin streptomycin and 50 µg/mL ascorbic acid) and media was refreshed every 2-3 days. Osteoblast phenotype was observed within 7-11 days.

### Compact bone-derived osteoblasts (CB-OB) {#s4-3-2}

Bone-marrow-depleted bones, obtained after bone marrow cell isolation, were used as source of CB-OB. Epiphyseal ends of the bone were cut off and the remaining diaphysis were cut into small fragments (\<1 mm^2^ pieces). Bone fragments underwent a three-step enzymatic digest: (i) 10 mL αMEM (serum-free) + 125 µL 0.25% trypsin + 5 µL collagenase P (37°C, 15 min while rotating). (ii) Dispose supernatant and add 10 mL αMEM (serum-free) + 125 µL 0.25% trypsin + 10 µL 100 mg/mL collagenase P (37°C, 30 min while rotating). (iii) Dispose supernatant and add 10 mL αMEM (serum-free) + 125 µL 0.25% trypsin + 100 µL 100mg/mL collagenase II (37°C, 1 hr while rotating, shake vigorously every 10 min). Supernatant from final digest was disposed, bone fragments were rinsed with PBS and plated in 6-well plate in αMEM (10% FBS, 1% sodium pyruvate, 1% penicillin streptomycin and 50 µg/mL ampicillin) for 3-5 days to allow cell outgrowth from fragments. Cells were detached with trypsin, filtered through 40 µm membrane and plated at a density of 1×10^4 ^ per cm^2^ in osteoblastic differentiation medium (αMEM supplemented with 10% FBS, 1% sodium pyruvate, 1% penicillin streptomycin and 50 µg/mL ascorbic acid) 2-3 days prior to experiments. Primary osteoblast cultures were sub-cultured for up to 8 passages (1:10 passages).

### BMP-2 tranfected C2C12 cells (C2-OB) {#s4-3-3}

The C2C12 cell line (ATCC CRL-1772) stably transfected with BMP-2 (courtesy of Dr. M. Murshed, McGill University) was maintained in DMEM (supplemented with 1% penicillin streptomycin, 1% sodium pyruvate and 10% FBS) at 5% CO~2~, 37°C humidified atmosphere. Absence of mycoplasma contamination was verified in cryo-preserved stocks of C2-OB cells using the Venor GeM Mycoplasma PCR-based detection kit (Sigma MP0025). To further authenticate the osteoblast phenotype in the C2-OB cell line, osteogenic differentiation was induced with ascorbic acid (50 µg/mL) and changes in osteogenic gene expression after 7 days of culture were assessed by qRT-PCR. Significant increases in expression of osteoblast marker genes Runx2 (+37%, p=0.02), *Alpl* (+57%, p=0.03) and *Col1a1* (+172%, p\<0.001) were observed, while *Bmp2* expression was stable overtime, thereby confirming the osteoblastic phenotype in this cell-line. Cells between passages 6 and 10 were used in all experiments. 2-3 days prior to experiments, cells were plated at a density of 3×10^4^ cells per cm^2^.

Osteoblast phenotype {#s4-4}
--------------------

Cells were fixed with formalin (pH 7.4, 8 min) and rinsed with PBS (3x). Alkaline phosphatase (ALP) staining solution was prepared by combining 4.5 mg fast red violet salt dissolved in 3.75 mL H~2~O and 3.75 mL 0.2 M Tris-HCl, pH 8.3 with 0.75 mg Naphthol AS-MX phosphate disodium salt dissolved in 30 µL N,N-dimethylformamide. Sufficient staining solution was added to each well to ensure entire surface was covered (approx. 500 µL in 35 mm dish) and incubated at room temperature for 15 min, or until red precipitate formed. Cells were washed with H~2~O and observed under bright-field microscopy. Alkaline phosphate-positive cells were stained pinkish-red, while yellow hue was observed in alkaline phosphatase-negative cells.

Mechanical stimulation {#s4-5}
----------------------

### Local membrane deformation of a single cell {#s4-5-1}

Single osteoblastic cells were stimulated by local membrane deformation with a glass micropipette using a FemtoJet microinjector NI2 (Eppendorf Inc.). The micropipette was positioned approximately 10 µm from the cell membrane at a 45° angle from the horizontal plane and mechanically stimulated at a speed of 250 µm/s with a contact duration of 60 ms. Glass micropipettes were custom-made from glass capillary tubes (1.5 mm outer diameter, King Precision Glass Inc.) using a Sutter Pipette Puller (Flaming/Brown, model P-87).

### Bulk stimulation by turbulent fluid shear (tFSS) {#s4-5-2}

50% of the culture medium volume was manually withdrawn and replaced at an approximate speed of 2 resuspensions per second for an indicated number of *n* times (e.g., 10x tFSS corresponded to 50% vol displacement performed 10 times).

Intracellular calcium recording and analysis {#s4-6}
--------------------------------------------

Cells plated on glass-bottom plates (MatTek Corporation) were loaded with a ratiometric fluorescent calcium dye Fura2-AM (r.t., 30 min), washed with PS and allowed to acclimatize for 10 min to reduce the effects of mechanical agitation. \[Ca^2+^\]~i~ was recorded at a sampling rate of 2 images per second (2 Hz) using a Nikon T2000 fluorescent inverted microscope with 40x objective ([@bib39]). Recordings consisted of \~10 s baseline \[Ca^2+^\]~i~ and additional 110--170 s following application of mechanical stimulation or treatment. The excitation wavelength was alternated between 340 and 380 nm using an ultra-high-speed wavelength switching illumination system (Lambda DG-4, Quorum Technologies). Regions of interest (ROI) were manually defined and the ratio of the fluorescent emission at 510 nm, following 340 and 380 nm excitation (f340/f380), was calculated and exported using the imaging software (Volocity, Improvision). All data were imported into an excel spreadsheet for characterization using a MATLAB algorithm previously described ([@bib21]). The following parameters were obtained for statistical analysis: amplitude (amp; magnitude of response), activation time (t~10%-90%~; time between 10% and 90% of maximum response), and decay constant (τ~decay~) of exponential decay region of deactivation phase of transient response. For micropipette stimulation experiments, secondary responsiveness was calculated as the percentage of neighboring cells exhibiting \[Ca^2+^\]~i~ elevations.

Vesicle labeling, imaging, and analysis {#s4-7}
---------------------------------------

### Localization {#s4-7-1}

To visualize the intracellular distribution and colocalization of quinacrine and MANT-ATP, cells were loaded with MANT-ATP (5 µM, overnight, 37°C) followed by quinacrine (10 µM, 15 min, room temperature). Cells were washed with PS and imaged using a Zeiss LSM 780 laser scanning confocal microscope. An argon and diode laser were used as light sources (ex. 405 nm and 458 nm) and the detection wavelength ranges were set to 410--470 nm and 490--570 nm to ensure separation of overlapping emission spectra, for MANT-ATP and quinacrine, respectively. Images were acquired using a Zeiss Plan-Apochromat 63x/1.40 Oil immersion objective lens. Subsequent analysis was carried out using ImageJ (National Institutes of Health, USA). Vesicular density was determined using ImageJ by counting number of intracellular quinacrine-positive puncta and normalizing count to cell surface area.

### Kinetics {#s4-7-2}

To study vesicular release kinetics, time-lapse recordings of quinacrine-loaded cells were acquired with a Nikon T2000 fluorescent inverted microscope after a 10-min period of post-stain acclimatization to minimize the effects of mechanical agitation. Quinacrine-rich vesicles were imaged using a 40x objective at a sampling frequency of 2 Hz for 2 min. To minimize the phototoxic effects of quinacrine, the excitation intensity was set to 33% of peak intensity and the shutter was shut in between 100 ms exposures. Image sequences were exported using the imaging software Volocity (Improvision) for subsequent analysis in ImageJ. To quantify the kinetics of vesicular release, sudden losses of fluorescence were monitored. Vesicles that gradually came in and out of focus did not qualify as release events. SparkSpotter (Babraham Bioinformatics, UK), an ImageJ plugin, was used to identify release events in temporally reversed and contrast-enhanced image stacks, so that the loss of fluorescence would instead be detected as a sudden increase by the spark identifying algorithm. Acquired data was visually evaluated and represented as either release events per second or cumulative vesicular release for indicated time frame, normalized to unit area.

ATP measurements {#s4-8}
----------------

### Fluorescence recordings of \[ATP\]*~e~* {#s4-8-1}

10 nM D-luciferin- and 2 µg/mL fire-fly luciferase-containing physiological solution (PS) was added to C2-OB and extracellular luciferin fluorescence was recorded (380 ex/510 em). Using an ATP standard calibration curve ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), pericellular (\<15 µm from stimulated cell) ATP concentrations \[ATP\] were obtained. The amount of ATP released by individual cells was estimated by fitting the diffusion profile obtained from the fluorescence measurements with the diffusion equation for release from an instantaneous plane source ([@bib7]).$$\left\lbrack {ATP} \right\rbrack(x,\ t) = \frac{M}{2(\pi Dt)^{\frac{1}{2}}}exp\left( \frac{- x^{2}}{4Dt} \right)$$where \[*ATP*\](*x*,*t*) is ATP concentration at distance *x* from the source, at time *t* from the moment of release. *M* is the amount of ATP released at *x* = 0, *t* = 0. *D* is ATP diffusion coefficient, assumed to be 3.3×10^-6^ cm^2^/s at 22°C ([@bib28]).

### Bioluminescent recordings of \[ATP\]~e~ {#s4-8-2}

Bioluminescence assay was used to measure ATP content in supernatant samples. Luciferin-luciferase reaction solution contained 0.45 µM D-luciferin and 40 µg/mL firefly-luciferase in bioluminsecence reaction buffer. 10 µL supernatants were sampled after tFSS stimulation, added into a glass cuvette containing 100 µL of luciferin-luciferase reaction solution, and measured using FB 12 single tube luminometer. Total cellular ATP content was measured in RIPA-lysed samples. \[ATP\] was estimated using calibration curves ([Figure 6---figure supplement 5](#fig6s5){ref-type="fig"}).

Membrane integrity assays {#s4-9}
-------------------------

### Dye leakage {#s4-9-1}

Fura2-loaded osteoblastic cells were mechanically stimulated with a glass micropipette and 510 nm emission intensity was monitored after 340 nm excitation ([@bib40]). Unless stated otherwise, Fura2 leakage refers to the percentage of cells that were severely injured (sIn; complete loss of intracellular Fura2 fluorescence) following micropipette stimulation.

### Dye uptake {#s4-9-2}

0.08% TB or 10 µM R-dextran were added before or 5 min after mechanical stimulation, washed with PS, and the proportion of dye-positive cells were assessed by microscopy.

### Cytosolic leakage {#s4-9-3}

Extracellular lactate dehydrogenase (LDH) was measured using Cytotoxicity Detection Kit^PLUS^. Total cellular LDH content was measured in RIPA-lysed samples.

### Cell viability {#s4-9-4}

1 hr after tFSS, AlamarBlue assay was performed according to manufacturer's protocol. Cell viability was reported as percentage of total cells.

*In vivo* bone loading {#s4-10}
----------------------

10-week-old female C57Bl/6J mice were injected intraperitoneally with LFTR-Dex either 30 min before or 20 min after loading. *In vivo* cyclic compressive loading at 600 µε or 1200 µε was applied for 5 min ([@bib43]). Mice were randomized into two groups, anesthetized, and *in vivo* cyclic compressive loading was applied to the left tibia (216 cycles at 4 Hz the mean mouse locomotor stride frequency \[[@bib5]\]), delivering a maximum force of −5.5 N and −11 N, which engenders 600 µε or 1200 µε, respectively at the periosteal surface of the tibia mid-diaphysis in these mice determined by prior *in vivo* strain gauging studies ([@bib1]). Previous reports have shown strain levels of 200--600 µε are engendered on the medial tibia during walking in the mouse ([@bib8]; [@bib37]). Strain levels of 1200 µε are considered supraphysiological resulting in a robust bone formation response after 5 days of mouse tibial loading ([@bib43]; [@bib2]) and altered gene expression after only a single bout of loading ([@bib45]; [@bib12]). Mice ambulated freely after controlled loading, and were euthanized 50 min post-dye-injection, weighed ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) and tibiae and calvariae were dissected and fixed in formalin. Tibia lengths were measured ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}) and mid-shaft tibiae were cut into fragments, which were immunofluorescently labeled for sclerostin, counterstained with DAPI, and visualized with Nikon T2000 fluorescence inverted microscope. Right non-loaded tibiae were used as an internal control. Female mice were used instead of males to minimize in-cage aggression and related variations in background mechanical-loading. Experimenter was blinded during image analysis.

Immunoblotting {#s4-11}
--------------

Cell lysates were extracted in RIPA lysis buffer and centrifuged (12 000 rpm, 10 min, 4°C). Supernatants were collected and protein concentration were determined using Quant-iT protein assay kit (Invitrogen). 70 µg cell lysates were separated on a 10% SDS-PAGE and transferred to a nitrocellulose membrane (0.45 µm, 162--0115, Bio-Rat) using a 10 mM sodium borate buffer. The membranes were blocked in 5% BSA in TBST buffer (1 hr, room temperature) followed by overnight incubation at 4°C with primary antibodies (1:1000 dilution, 5% BSA in TBST) for phosphorylated PKC isoforms: p-PKC (pan; βII Ser660), p-PKCδ/θ (Ser643/676), p-PKD/PKCµ (Ser744/748) and p-PKCζ/λ (Thr410/403), or for total PKC isoforms: PKCα, PKCδ, PKD/PKCµ and PKCζ. Blots were washed and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 hr at room temperature (1:1000 dilution, 5% BSA in TBST) and visualized with a chemiluminescence system.

GAP junction functional assay {#s4-12}
-----------------------------

Cells were scraped in the presence of GAP-junction permeable dye Lucifer yellow (LY, 10 µM), incubated for 2 min (37°C), rinsed and fixed with formalin (pH 7.4, 8 min). Dye transfer was visualized using wide-field epifluorescence microscopy and cell-cell coupling was visually determined by bright-field microscopy. Cells that were not initially scraped but were physically coupled and LY-positive after 2 min of staining were reported as a percentage of total cells that were physically coupled to scraped neighbors.

Statistical analysis {#s4-13}
--------------------

Data are representative results or means ± standard errors (S.E.M). Curve fittings and \[Ca^2+^\]~i~ transient characterization was done in MATLAB (MathWorks). Sample sizes for *in vitro* experiments indicate the total number of biological replicates (specified in figure legends as number of stimulated cells or number of independent cultures, which were isolated from different mice for primary OB, or represent different plating dates for C2-OB) pooled across a minimum of three independent experiments. For *in vivo* experiments, sample sizes indicate number of animals. Statistical significance was assessed by ANOVA followed by Bonferroni post-hoc test, significance levels are reported as single symbol (\*p\<0.05), double symbol (\*\*p\<0.01) or triple symbol (\*\*\*p\<0.001).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Mechanically-stimulated ATP release from murine bone cells is regulated by a balance of injury and repair\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Miguel A. Valverde as Guest Reviewing Editor and Vivek Malhotra as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Margarita Calvo (Reviewer \#2); Paul McNeil (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Overall, this is an interesting manuscript that seeks to explain the mechano-adaptive mechanism of bone cells to repair an injured plasma membrane. The data support a model whereby mechanical stress triggers a response involving ATP release through the disrupted membrane and calcium/PKC dependent vesicular exocytosis to repair the membrane. This is a novel mechanism based on a combination of imaging and functional assays to evaluate the response of both in vitro and in vivo bone cells.

Summary:

Mechanical signals play a critical role in the cellular/tissue regulation of the osteorticular system. Despite the importance of the mechanical loading in osteoarticular system health and disease, the mechanisms that participate in the maintenance of the integrity of the individual cells exposed to cyclical mechanical loading are not fully understood. Recently, different mechanoosmosensitive ion channels have been implicated in the homeostatic response to mechanical loading. The manuscript by Mikolajewicz and colleagues use different cultured bone cells as well as in vivo assays to address the how non-lethal cell membrane injury triggers cell membrane repair. They show that mechanical stress, generates ATP release, intracellular calcium signals and Ca^2+^/PKC dependent membrane exocytosis.

The authors build a model in which the mechanical stimulation results in membrane disruption, which leads to ATP efflux and Ca^2+^ influx, triggering vesicular exocytosis and membrane repair that then limits ATP release. Although it seems a convincing model we would like to see further work done to evaluate the contribution of mechanosensitive ion channels in the repairing mechanism.

Overall, this manuscript is well written (but with overcrowded figures), interesting, timely and will add an interesting angle to the mechanisms of cellular response to mechanical loading.

Essential revisions:

1\) It will be essential to evaluate the role of mechanosensitive ion channels in the repair mechanisms. Piezo1/2 and TRPV4 channels have been proposed to play a key role in many mechanobiological responses of different cell types, particularly the osteo-articular system. Therefore, their contribution should be evaluated by experiments in which their activity is assessed by loss-of-function e.g. implementing knockdown by applying si/shRNA and/or specific pharmacological approaches.

2\) For the quantification of the western blots, total as well as phosphorylated forms of PKC and PKD should be used for normalization (phospho/total).

Other points to consider:

1\) Some of the experiments were run in one type of cells and other ones in other cells? Is there any rationale on using one or the other cell type? If yes, it need to be explained clearly in the text.

2\) Please define what the N numbers refer to in each figure.

3\) For western blots, please provide the entire gel (as a supplementary figure).

4\) Figures are too busy, particularly Figure 6. Can you please simply/reorganize this figure to facilitate its reading/understanding.

*Reviewer \#1:*

\"Mechanically-stimulated ATP release from murine bone cells is regulated by a balance of injury and repair\" provides interesting and novel observations on mechanotransduction in osteoblasts that might be relevant for in-vivo function, with basic science and biomedical-translational relevance.

I would encourage the authors to explore more in-depth an eventual role of Piezo ion channels in the observed mechanotransduction. They go to great lengths to probe an array of molecules involved in mechanotransduction, Piezo should also be appreciated with more dedication.

Besides this issue, I have not identified additional major concerns.

*Reviewer \#2:*

In this paper, Dr Komarova et al. describe a regulatory mechanism that controls the amount of ATP released in response to reversible membrane injury. They describe that exocytosis of ATP-containing vesicles can limit the efflux of intracellular ATP through the injured membranes (which is of a much larger scale). This is a newly described mechanism of cell resilience against mechanical forces.

I have a few questions that would like the authors to address:

1\) You initially say that you tested osteoblasts from three different sources: two primary cultures (BM-OB and CB-OB) and one cell line (C2-OB). I may have missed it, but why did you choose to do some of the experiments in some of these cells and other ones in other cells? Is there any rationale on using one or the other cell type? If yes, it need to be explained clearly in the text.

2\) In Figure 1 you show experiments in the 3 different cell types and there are significant differences between them. But these are not mentioned neither discussed in the manuscript. Could you please discuss.

3\) Regarding n numbers; I understood that n=1 in the in vivo experiment means one animal. But in the in vitro experiments what do you define as n=1? Is one plate with x number of wells (biological replicates)? Or n=1 is one well? In this case n=x could mean that there are x wells coming all from the same original culture?

4\) In the in vivo experiments, why did you only use female mice? Any rationale behind this? Could you explain in the text?

5\) For the western blots I would like to see the entire gel, not just to show the band (if it makes the figure complicated you can add the gels as supplemental). But this is important for future replications.

6\) Also for WB, why did you not measure total PKC and PKD. You should normalise the quantity of phosphoPKC or phosphoPKD to the total amount of these proteins (phsopho/total).

7\) Figure 6 is far too busy and hard to understand. Could you please make it simpler or bigger? (Or divide in two figures when you include the bands and measurements of total kinases over phospho).

8\) I think a schematic representation or diagram summarizing your results as a last figure could help a lot to understand the results and will give a clearer message.

*Reviewer \#3:*

This paper adds significantly to a novel, recently proposed (Yu et al., 2017) hypothesis for explaining how bone adapts to mechanical stress. Physiologically relevant mechanical stresses are observed in vitro and in vivo to disrupt osteocyte plasma membranes. These membrane disruptions are not necessarily lethal but can be repaired allowing cell survival of this injury. However the disruption is thought to initiate signaling, such as a rise in intracellular calcium, that then leads to bone adaptation events. Here the authors show that ATP is released through osteocyte disruptions, a second signaling mechanism that might lead to an adaptive response. The sections of the paper dealing with repair are less strong as the authors do not have a technique for quantitative assay of this event.

10.7554/eLife.37812.035

Author response

> Reviewer \#1:
>
> \[...\] I would encourage the authors to explore more in-depth an eventual role of Piezo ion channels in the observed mechanotransduction. They go to great lengths to probe an array of molecules involved in mechanotransduction, Piezo should also be appreciated with more dedication.

Piezo channels have been implicated in mechanically-stimulated ATP release in red blood cells \[1\] and urothelial cells \[2\], and TRPV channels were shown to be involved in ATP release in urothelial \[3, 4\] and renal cells \[5\], cholangiocytes \[6\], as well as alveolar and bronchial epithelial cells \[7\]. Both Piezo 1/2 and TRPV4 channels have been previously demonstrated to be sensitive to Gd^3+^ \[8, 9\]. However, our data indicate that ATP release from mechanically-stimulated osteoblasts is not inhibited by Gd^3+^ (Figure 3---figure supplement 1B). We have additionally investigated the involvement of TRPV4 using its specific inhibitors HC 067047 \[10\] and GSK 2193874 \[11\], and are now providing new data addressing the involvement of Piezo1 using its specific inhibitor GsMTx-4 \[12\]. Consistent with the effects of Gd^3+^, specific inhibitors of Piezo 1 and TRPV4 were not effective in inhibiting mechanically stimulated ATP release from osteoblasts (Figure 3---figure supplement 1). Our findings are consistent with previous work that tested the involvement of Piezo1 and TRPV4 in osteoblasts using Gd^3+^ \[13\].

> Besides this issue, I have not identified additional major concerns.
>
> Reviewer \#2:
>
> \[...\] 1) You initially say that you tested osteoblasts from three different sources: two primary cultures (BM-OB and CB-OB) and one cell line (C2-OB). I may have missed it, but why did you choose to do some of the experiments in some of these cells and other ones in other cells? Is there any rationale on using one or the other cell type? If yes, it need to be explained clearly in the text.

During the study, we performed all the exploratory experiments in a C2C12-BMP2 cell line due to easy access and consideration for reducing animal use. To validate these findings, we used primary cultures of mouse osteoblasts. Since both bone-marrow-derived \[14, 15\] and compact-bone derived \[16, 17\] osteoblast cultures are used in the literature, we explored both cultures, and obtained qualitatively similar results, in spite of differences in the origin and differentiation state of the cells (pre-osteoblast-like in bone marrow derived cultures and late OB-osteocytes-like in compact bone-derived cultures). Since compact-bone derived late osteoblasts/osteocytes are closer to the in vivo model we used in this study, we continued using these cells for data validation throughout the study. Nevertheless, we included the data obtained in bone-marrow-derived cultures, since they demonstrate a side-by-side comparison for responses in osteoblastic cells obtained through different ex vivo protocols. While not a primary objective of this study, we believe that such data is important for understanding how different in vitro models behave. We have now included this clarification in the 'Cell Cultures' section of the Materials and methods.

> 2\) In Figure 1 you show experiments in the 3 different cell types and there are significant differences between them. But these are not mentioned neither discussed in the manuscript. Could you please discuss.

As suggested, we have now discussed the differences in GAP junction involvement in bone-marrow-derived osteoblasts in the subsection "Mechanically-stimulated osteoblasts release ATP that induces calcium responses I n non-stimulated neighboring cells".

> 3\) Regarding n numbers; I understood that n=1 in the in vivo experiment means one animal. But in the in vitro experiments what do you define as n=1? Is one plate with x number of wells (biological replicates)? Or n=1 is one well? In this case n=x could mean that there are x wells coming all from the same original culture?

We have now clarified what n refers to in the 'Statistical Analysis' section of the Materials and methods, and in the legend for each figure.

> 4\) In the in vivo experiments, why did you only use female mice? Any rationale behind this? Could you explain in the text?

C57Bl/6J male mice demonstrate significant in-cage fighting compared to females, which introduces higher variation in their background mechanical loading. This is expected to result in a less consistent mechanoresponsiveness and thus require more experimental sample size (i.e., more animals). As suggested, we have now clarified this in the 'In-vivo Bone Loading' section of the Materials and methods.

> 5\) For the western blots I would like to see the entire gel, not just to show the band (if it makes the figure complicated you can add the gels as supplemental). But this is important for future replications.
>
> 6\) Also for WB, why did you not measure total PKC and PKD. You should normalise the quantity of phosphoPKC or phosphoPKD to the total amount of these proteins (phsopho/total).

As suggested in comments 5 and 6, we have now normalized phosphoPKC and phosphoPKD to total PKC or PKD (Figure 6E) and provided complete gels in Figure 6---figure supplement 4.

> 7\) Figure 6 is far too busy and hard to understand. Could you please make it simpler or bigger? (Or divide in two figures when you include the bands and measurements of total kinases over phospho).
>
> 8\) I think a schematic representation or diagram summarizing your results as a last figure could help a lot to understand the results and will give a clearer message.

As suggested in comments 7 and 8, we have now moved some data from Figure 6 to Figure 6---figure supplement 2 and presented the schematic in Figure 7.
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